Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Rhea-AI Summary

Telomir Pharmaceuticals (NASDAQ:TELO) completed its acquisition of TELI Pharmaceuticals on April 24, 2026, consolidating global rights to Telomir-1 (Telomir-Zn) under one company and making TELI a wholly owned subsidiary.

The deal included $1.0 million funded at closing and up to an additional $4.0 million in optional, milestone-based contributions tied to IND acceptance and Phase 1/2 initiation. Telomir has submitted an IND for Telomir-Zn aimed at advanced/metastatic triple-negative breast cancer and plans a Phase 1/2 oral monotherapy trial if cleared.

Positive

• Consolidated global rights to Telomir-1 (Telomir-Zn)
• TELI now a wholly owned Telomir subsidiary
• $1.0 million cash received at closing
• Up to $4.0 million available via milestone contributions
• IND for Telomir-Zn submitted to FDA

Negative

• Additional up-to-$4.0M funding is optional and participation-dependent
• Shares issued subject to six-month lock-up, limiting immediate liquidity

News Market Reaction – TELO

+1.45%

+1.45% Session close to close

In the Apr 24 session, TELO gained 1.45%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement consolidates global rights to Telomir-1 (Telomir-Zn) via a stock-for-stock acquisi...

Analysis

This announcement consolidates global rights to Telomir-1 (Telomir-Zn) via a stock-for-stock acquisition, adding $1.0 million in immediate funding and up to $4.0 million in milestone-based support tied to IND acceptance and a Phase 1/2 trial. It follows a series of positive preclinical and regulatory steps for Telomir-1. Investors may watch for FDA IND clearance, timing of the planned advanced/metastatic TNBC trial, and the degree to which former TELI shareholders participate in optional milestone funding.

Key Figures

Funding at closing: $1.0 million Milestone-based funding: Up to $4.0 million Planned trial phase: Phase 1/2 +1 more

4 metrics

Funding at closing $1.0 million Capital received in connection with TELI acquisition closing

Milestone-based funding Up to $4.0 million Optional contributions tied to IND acceptance and Phase 1/2 initiation

Planned trial phase Phase 1/2 Planned clinical trial of Telomir-Zn in advanced/metastatic TNBC if IND cleared

Lock-up period Six months Shares issued to former TELI shareholders subject to six‑month lock-up

Historical Context

5 past events · Latest: Mar 31 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 31	IND submission	Positive	+14.0%	Filed IND for Telomir-1 in advanced/metastatic TNBC with Phase 1/2 plan.
Feb 17	Preclinical efficacy data	Positive	+5.5%	Reported strong in vitro TNBC cell mortality supporting Telomir-Zn activity.
Feb 05	Mechanism-of-action data	Positive	-3.5%	Showed rapid zinc increase and iron reduction without cytotoxicity in cells.
Jan 05	Animal model efficacy	Positive	+11.2%	Demonstrated reduced tumor growth and metastasis in TNBC animal models.
Dec 18	GLP safety results	Positive	+1.5%	Reported favorable GLP toxicology with no dose-limiting toxicities for Telomir-1.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive Telomir-1 milestones have generally aligned with positive price reactions, with one notable divergence on favorable mechanistic data.

Recent Company History

Over the last six months, Telomir has repeatedly highlighted progress for Telomir-1 (Telomir-Zn), including favorable GLP safety on Dec 18, 2025, zebrafish efficacy data on Jan 5, 2026, and mechanistic metal-modulation data on Feb 5, 2026. Subsequent TNBC in vitro data on Feb 17 and the IND submission on Mar 31 drove price moves up to 14.04%. Today’s acquisition news extends this trajectory by consolidating global rights and pairing them with targeted development funding.

Key Terms

investigational new drug (ind), phase 1/2 clinical trial, triple-negative breast cancer, metastatic, +4 more

8 terms

investigational new drug (ind) regulatory

"Combined with our recent IND submission for Telomir-Zn, this positions the Company"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

phase 1/2 clinical trial medical

"plans to initiate a Phase 1/2 clinical trial evaluating Telomir-Zn as an oral"

A phase 1/2 clinical trial is an early human study that combines first-in-people safety and dosing checks (phase 1) with an initial look at whether the treatment appears to work (phase 2). Think of it as a short test drive where researchers both confirm the product won’t cause serious harm and gather early signs it could be effective; for investors, successful results reduce risk and can unlock value-creating milestones like larger trials or regulatory discussions.

triple-negative breast cancer medical

"for the treatment of advanced and metastatic triple-negative breast cancer."

Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.

metastatic medical

"for the treatment of advanced and metastatic triple-negative breast cancer."

Metastatic describes cancer that has spread from its original spot to other organs or tissues, like weeds moving from one garden bed into several others. For investors, metastatic disease matters because it often requires more complex, long-term treatments, larger clinical trials, and can drive demand for specialized drugs and diagnostics—factors that affect a drug’s development costs, regulatory risk, market size, and potential revenue.

oral monotherapy medical

"trial evaluating Telomir-Zn as an oral monotherapy in patients with advanced"

Oral monotherapy is treatment using a single drug taken by mouth rather than combining multiple medicines or using injections. For investors, it matters because single-pill oral therapies are easier for patients to take, often cheaper to manufacture and distribute, and provide clearer clinical and regulatory readouts—factors that can speed adoption, simplify marketing and influence a drug’s commercial potential, like choosing one reliable tool instead of a whole toolbox.

stock-for-stock acquisition financial

"Transaction completed as a stock-for-stock acquisition Former TELI shareholders"

A stock-for-stock acquisition is a deal where one company buys another by offering its own shares instead of cash, so shareholders of the target receive shares in the buyer. For investors this matters because it changes who owns what, can dilute or concentrate ownership, and ties the value you receive to the buyer’s future stock performance—think of swapping cash for a bundle of trading cards whose worth can rise or fall.

lock-up financial

"Shares issued are subject to a six-month lock-up, subject to customary"

A lock-up is an agreement that prevents company insiders, early investors or employees from selling their shares for a set period after a public share offering. It matters to investors because it temporarily limits the number of shares available to trade—like a scheduled hold on extra inventory—and when that hold ends a large number of shares can enter the market, potentially putting downward pressure on the stock price and revealing insiders’ confidence in the company.

clinical milestones medical

"optional milestone-based capital support aligned with key clinical milestones."

Clinical milestones are the key, trackable events in the development of a medical treatment or diagnostic — for example completing a patient study, meeting the study’s main goal, or filing for regulatory approval. They act like checkpoints on a roadmap, showing progress and reducing uncertainty; investors watch them because each milestone can meaningfully change a project's risk, funding needs, partnership prospects and the value of companies involved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones.

MIAMI, FL / ACCESS Newswire / April 24, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, today announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals, Inc. ("TELI").

The transaction, which was approved by Telomir's shareholders at the Company's Annual Meeting held on March 23, 2026, establishes Telomir as the sole holder of the global rights of Telomir-1 (Telomir-Zn), consolidating worldwide rights under a single corporate structure.

Management Commentary

Erez Aminov, Chief Executive Officer of Telomir, stated:

"The closing of this transaction represents a defining milestone for Telomir. By securing worldwide rights to Telomir-1 (Telomir-Zn), we have established a globally unified platform as we advance toward clinical development.

Combined with our recent IND submission for Telomir-Zn, this positions the Company to progress into the clinic while maintaining the flexibility to evaluate global partnership opportunities."

The acquisition eliminates prior geographic fragmentation of the Telomir-1 (Telomir-Zn) platform and provides Telomir with full control over development and potential commercialization across major international markets. Prior to the transaction, North American and international rights were held separately.

In connection with the transaction, the Company received $1.0 million in funding at closing and may receive up to an additional $4.0 million in milestone-based contributions from certain former TELI shareholders. These potential contributions are tied to key development milestones, including acceptance of an Investigational New Drug (IND) application and initiation of a Phase 1/2 clinical trial, and are subject to participation by such shareholders, aligning potential capital support with clinical advancement.

Clinical Development

The closing follows Telomir's recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Telomir-Zn for the treatment of advanced and metastatic triple-negative breast cancer.

If the IND is cleared, the Company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-Zn as an oral monotherapy in patients with advanced or metastatic triple-negative breast cancer.

Transaction Summary

• TELI is now a wholly owned subsidiary of Telomir

• Transaction completed as a stock-for-stock acquisition

• Former TELI shareholders received shares of Telomir common stock based on an independently determined exchange ratio

• Shares issued are subject to a six-month lock-up, subject to customary exceptions

• Transaction includes $1.0 million funded at closing and up to an additional $4.0 million in optional milestone-based contributions, subject to participation by such shareholders

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a biotechnology company developing small-molecule therapeutics designed to target epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Its lead candidate, Telomir-1 (Telomir-Zn), is an investigational therapy that has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, epigenetic regulation, mitochondrial function, and genomic stability.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits of the acquisition, the Company's plans for clinical development, the potential for additional capital contributions, and the Company's ability to pursue strategic partnerships.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, the Company's ability to obtain regulatory clearance for its IND, the timing and success of clinical trials, the availability of additional funding, and other risks described in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information

Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

FAQ

What did Telomir (TELO) acquire from TELI on April 24, 2026?

Telomir acquired full global ownership of Telomir-1 (Telomir-Zn) and made TELI a wholly owned subsidiary. According to Telomir, the transaction was a stock-for-stock acquisition with issued shares subject to a six-month lock-up and customary exceptions.

How much cash did Telomir (TELO) receive at closing and are there future payments?

Telomir received $1.0 million at closing and may receive up to $4.0 million in milestone-based contributions. According to Telomir, the additional payments are optional and tied to IND acceptance and Phase 1/2 trial initiation, subject to shareholder participation.

What is the regulatory status of Telomir-Zn after the acquisition (TELO)?

Telomir has submitted an IND to the FDA for Telomir-Zn targeting advanced/metastatic triple-negative breast cancer. According to Telomir, if the IND is cleared, the company plans to initiate a Phase 1/2 oral monotherapy clinical trial.

How will the acquisition affect Telomir's development rights for Telomir-Zn (TELO)?

The acquisition centralizes worldwide development and commercialization rights for Telomir-Zn under Telomir. According to Telomir, this removes prior geographic fragmentation and gives full control over global development strategy and partnership options.

What are the immediate shareholder effects from the TELI acquisition for Telomir (TELO)?

Former TELI shareholders received Telomir common stock under an independent exchange ratio; shares have a six-month lock-up. According to Telomir, the transaction was approved at its March 23, 2026 annual meeting and closed April 24, 2026.